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Abstract
Background: Multiple protein or microRNA markers have been recognized to contribute to the progression and
recurrence of cervical cancers. Particular those, which are associated with the chemo- or radio-resistance of cervical
cancers, have been proposed to be promising and to facilitate the definition for cervical cancer treatment options.
Methods: This study was designed to explore the potential prognosis value of p21-activated kinase (PAK)-4 in
cervical cancer, via the Kaplan–Meier analysis, log-rank test and Cox regression analysis, and then to investigate the
regulatory role of PAK4 in the cisplatin resistance in cervical cancer cells, via the strategies of both PAK4 overexpression
and PAK4 knockout.
Results: It was demonstrated that PAK4 was upregulated in cervical cancer tissues, in an association with the cancer’s
malignance variables such as FIGO stage, lymph node or distant metastasis and the poor histological grade. The high
PAK4 expression was also independently associated with poor prognosis to cervical cancer patients. Moreover,
PAK4 confers cisplatin resistance in cervical cancer Hela or Caski cells. In addition, the PI3K/Akt pathway has been
implicated in the PAK4-confered cisplatin resistance. And the PI3K/Akt inhibitor, LY294002, markedly deteriorated
the cisplatin-mediated viability reduction of Hela or Caski cells, indicating the involvement of PI3K/Akt pathway in
the cisplatin resistance in cervical cancer cells.
Conclusion: This study has confirmed the significant prognostic role of PAK4 level in cervical cancer patients and
has recognized the regulatory role in cervical cancer progression. Moreover, our study has indicated that PAK4
also confers the chemoresistance of cervical cancer cells in a PI3K/Akt-dependent way. Thus, our study indicates
PAK4 as a promising marker for cervical cancer treatment.
Background
Cervical cancer records the third most common women
malignancy, with an estimated global incidence of over
500,000 new cases [1], and leads secondly the death
cause of women world widely, with an estimated
530,000 deaths per year [2]. Multistep processes and
molecular markers have been confirmed to be involved
in the tumorigenesis, invasiveness of cervical cancers [3].
Although radiotherapy, chemotherapy and surgery have
recently been standardized for patients with cervical
cancer, clinical outcomes still vary significantly. There-
fore, it is important to expand the knowledge of the mo-
lecular pathways and markers of cervical cancers to
identify prognostic markers and to improve therapeutic
strategies. Cervical cancer is clinically staged according
to such prognostic factors as clinical stage at diagnosis
time, tumor size, vascular invasion, and adjacent/lymph-
atic metastasis. And such staging define the treatment
option for single surgery or for multidisciplinary treat-
ments with either concurrent chemoradiation or with
neoadjuvant chemotherapy followed by surgery [4].
The etiology of cervical cancer has been largely attrib-
uted to infection of human papillomavirus (HPV) [5, 6].
However, HPV infection does not necessarily lead to
such cancer [7]. And accumulating studies gaining
insight into other molecular characterization of it have
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identified many novel biological factors, which directly
or indirectly regulate cell cycle, apoptosis, angiogenesis,
or invasive or metastatic potential of cervical cancers
[8–10]. Moreover, since the therapeutic resistance is a
common phenomenon in cervical cancers, particularly
in patients with advanced, recurrent, and metastatic dis-
ease [7]. Thus, biomarkers of proteins [11, 12] and
microRNAs [13–15], which are associated with the
chemo- radio-resistance of cervical cancer have been
proposed to be promising and to facilitate the definition
for cervical cancer treatment options.
The small GTPases, i.e. Ras, Rho, Rac and Cdc42 are a
family of G-proteins in the cytosol function independ-
ently as a hydrolase enzyme (bind and hydrolyze guano-
sine triphosphate (GTP)). p21-activated kinases (PAKs)
are a family of serine/threonine protein kinases (PAK1-
6) which are best characterized downstream effectors of
Rac and Cdc42 [16]. PAKs have increasingly recognized
to be overexpressed and/or hyperactivated in several hu-
man tumors such as breast cancer, colon cancer, lung
cancer and gastric cancer [17, 18], closely correlating
with cancer development. PAKs are significantly relevant
to tumorigenesis by regulating the Ras-induced cell cycle
progression and metabolism [19, 20], epithelial–mesen-
chymal transition [21] and angiogenesis [22]. Besides,
PAK4 has been recognized to modulate the cancer mi-
gration and invasion via interacting with Met [23] or
with DGCR6L [18]. Moreover, PAK4 has recently been
found to confer cisplatin resistance in gastric cancer
cells [24] or in glioma [25]. However, the oncogenic role
of PAK4 in cervical cancer has not been reported.
This study was designed to explore the potential prog-
nosis value of PAK4 in cervical cancer, and then to in-
vestigate the regulatory role of PAK4 in the cisplatin
resistance in cervical cancer cells. Our results demon-
strate that PAK4 is closely associated with the develop-
ment and progression of cervical cancer and confers
cisplatin resistance in cervical cancer cells.
Methods
Cervical cancer patients
93 patients with cervical cancer of stage IB–IIIA, who
were registered between April 2013 and November 2014
in the Department of Gynecology, Tianjin Huanhu Hos-
pital were included in the present study. Among them,
68 cases were squamous cell carcinoma, the other 25
cases were adenocarcinoma, and 67 cases were HPV-
positive, whereas the other 26 cases were HPV-negative.
Detailed clinic-pathological information was shown in
table 1. Fresh cervical cancer tissues and their matched
peri-tumor tissues (2 cm away from the boundary of cer-
vical cancer tissues) were collected from the 93 cervical
cancer patients underwent surgery and were immedi-
ately frozen at −80 °C before use. Each patient was
pathologically confirmed by two pathologists, had no pre-
operative chemotherapy or radiotherapy, and was staged
according to the criteria of the International Federation of
Gynecology and Obstetrics (FIGO). External beam radio-
therapy was administered, with large-field radiation dose of
40–45 Gy to the whole pelvis, with 1.8-2 Gy/fraction and
five fractions weekly. For patients with Stage IIb or greater
disease, a small-field parametrial boost was given to a dose
of up to 60–90 Gy using a parallel-opposed anteroposterior
field. For the chemotherapy, cisplatin was given intraven-
ously with 40 mg/m2 once a week during the external
beam radiotherapy for the 44 patients with a FIGO stage of
Ib or IIa. For the 49 patients with a FIGO stage of IIb or
IIIa, two cycles of 60 mg/m2 docetaxel and 80 mg/m2 cis-
platin during the external beam radiotherapy. Overall sur-
vival (OS) time was calculated from the date of the initial
surgical operation to death. Follow-up for all patients was
Table 1 Association PAK4 expression with clinicopathological
features of human cervical cancer
Characteristics No.
(n = 95)
High PAK4 Low PAK4 P value
N % N %
Age (years) 93 0.42131
<65 56 24 55.81 32 64.00
≥65 37 19 44.19 18 36.00
Tumor size (cm) 0.59763
<4 46 20 46.51 26 52.00
≥4 47 23 53.49 24 48.00
HPV 0.99205
Positive 67 31 72.09 36 72.00
Negative 26 12 27.91 14 28.00
Tumor histology 0.25219
Squamous 68 29 67.44 39 78.00
Adenocarcinoma 25 14 32.56 11 22.00
FIGO stage 0.02888*
Ib 24 6 13.95 18 36.00
IIa 20 8 18.60 12 24.00
IIb 25 13 30.23 12 24.00
IIIa 24 16 37.21 8 16.00
LN metastasis 0.00525
Positive 38 24 55.81 14 27.45
Negative 56 19 44.19 37 72.55
Distant metastasis 0.02105
Positive 26 17 39.53 9 18.00
Negative 67 26 60.47 41 82.00
Histological grade 0.03464
Poor 41 24 55.81 17 34.00
Well/moderade 52 19 44.19 33 66.00
*: with significance
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performed every 2 months for the first 2 years, every
4 months for the third year, and every 6 months for the 4
to 5 years. This study was approved by the Research Ethics
Committee of the Tianjin Huanhu Hospital. Written in-
formed consent was obtained from each patient in this
study.*: with significance.
Cell culture and treatment
Human cervical cancer Hela and Caski cells were pur-
chased from American Type Culture Collection (ATCC)
(Rockville, MD, USA) and were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) (for Hela cells) or
RPMI-1640 medium (for Caski cells), which was supple-
mented with 10 % fetal bovine serum (FBS) (GIBCO,
Rockville, MD, USA), with 100 U/mL penicillin and
100 μg/mL streptomycin (CSPC, Shijiazhuang, China).
Cells were incubated in a humidified atmosphere at 37 °
C in 5 % CO2. For the cisplatin (Sigma-Aldrich, St.
Louis, MO, USA) treatment, 85 % or higher confluent
Hela or Caski cells were updated with DMEM or RPMI-
1640 medium supplemented with 2 % FBS, and with
5 μM (for Hela cells) or 10 μM (for CaSki cells) cisplatin
for 12, 24 or 48 h; For the PAK4 overexpression, the
open reading frame (ORF) of PAK4 (NM_005884.3) was
amplified by PCR with Phusion polymerase (New England
Biolabs, Ipswich, MA, USA) and with the primers (For-
ward primer: 5′-ATG TTT GGG AAG AGG AAG AAG
C-3′ and Reverse primer: 5′-TCA TCT GGT GCG GTT
CTG GCG-3′). The ORF sequence was then cloned into
the pcDNA3.1(+) vector (Invitrogen, Carlsbad, CA, USA),
with Hind III (New England BioLabs, Beverly, MA, USA)
and BamH I (New England BioLabs, Beverly, MA, USA)
as restriction enzymes, and with the chloramphenicol
acetyltransferase (CAT) as a control for PAK4. Hela or
Caski cells with more than 85 % confluence were trans-
fected with the recombinant pcDNA3.1(+)-PAK4 or
pcDNA3.1(+)-Con plasmid with Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA). For the PAK4 knockout,
the PAK4-specific siRNA (siRNA-PAK4) or siRNA-Con
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) with 25
or 50 nM were transfected with Lipofectamine RNAiMax
(Invitrogen, Carlsbad, CA, USA) into the Hela or Caski
cells to abrogate the HIWI expression. Phosphoinosi-
tide 3-kinase/ RAC-alpha serine/threonine-protein kin-
ase (PI3K/Akt) inhibitor, LY294002 (Thermo Scientific,
Rockford, IL, USA) was utilized with 10 or 20 nM (Hela
cells) or with 15 or 30 nM (Caski cells) to block the
PI3K/Akt pathway.
Quantitative analysis of PAK4 with RT-qPCR
To investigate the expression of PAK4 on mRNA level,
Real-time quantitative polymerase chain reaction (RT-
qPCR) was performed with PAK4-specific primers (For-
ward primer: 5′-CAG GGA AGG CAG GCA GCC GA-3′
and Reverse primer: 5′-CCT GTC ACC ACT GCC GCC
AC-3′) with the mRNA samples from cervical cancer tis-
sue specimens and cervical cancer Hela or Caski cells.
mRNA samples were prepared from the cervical cancer
tissues, peritumor tissues, or from Hela or Caski cells
with the TRIzol reagent (Invitrogen, Carlsbad, CA,
USA) according to the product’s manual, were supple-
mented with Rnase inhibitor (Takara, Tokyo, Japan),
and were stored at −80 °C before use. RT-qPCR proced-
ure was performed with SYBR green OneStep RT-PCR
Kit (Takara, Tokyo, Japan) according to the manufac-
turer’s manual. PAK mRNA level was calculated and
was presented as the relative level of PAK4 to β-actin
(as control) by ΔΔ Ct method [26].
Cell viability assay with MTT
Cell viability was examined with methyl thiazolyl tetra-
zoliym assay (MTT). Briefly, Hela or Caski cells which
were plated in 96-well plates with 85-90 % confluence
post the treatment with cisplatin, post the plasmid or
siRNA transfection or (and) post the treatment with
LY294002 were updated with 50 μl MTT solution for a
incubation at 37 °C for 2 h. Then cells were updated
with 150 μl DMSO was added to dissolve the precipitate
completely at room temperature. The optical density
was measured at 570 nm using a spectrophotometer
(Bio-Rad, Hercules, CA, USA).
Western blot analysis
Hela or Caski cells, post treatment, were harvested with
a cell scraper and were homogenized in an ice-cold Cell
lysis buffer (Bio-Rad, Hercules, CA, USA). Cellular ly-
sates were centrifugated with 12,000 × g for 30 min at
4 °C, and the supernatant was collected. Protein samples
were separated with 10 % (w/v) SDS-PAGE gel and were
transferred to a nitrocellulose membrane (Millipore,
Bedford, MA, USA). For analysis of PAK4, AKT with or
without phosphorylated Ser473, blots were incubated
with rabbit polyclone antibody against human PAK4
(diluted with 5 % BSA to 1: 500, PA5-15120, Thermo
Scientific, Rockford, IL, USA), against PAK4 with phos-
phorylated Ser474 (diluted with 5 % BSA to 1: 500, PA5-
17636, Thermo Scientific, Rockford, IL, USA), against
AKT with (diluted with 5 % BSA to 1: 500, No. 4685,
Cell Signaling Technology Inc., Danvers, MA, USA) or
without phosphorylated Ser473 (diluted with 5 % BSA to
1: 500, No. 4060, Cell Signaling Technology Inc., Danvers,
MA, USA) or against β-actin (diluted with 5 % BSA to 1:
1000, No.1320, Sinobio, Beijing, China) respectively. Then,
the specific binding on the membrane was probed with
Horseradish Peroxidase (HRP)-labeled anti-rabbit second-
ary antibody (diluted with 5 % BSA to 1: 1000, #7071, Cell
Signaling Technology Inc., Danvers, MA, USA) and with
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enhanced chemiluminescence (ECL) detection kit (Amer-
sham Pharmacia Biotech, Amersham, UK).
Statistical analysis
Statistical analysis was conducted using the GraphPad
Prism (GraphPad Software, La Jolla, CA, USA). The
chisquare test was used to evaluate the association of
PAK4 overexpression with clinic-pathological character-
istics. Kaplan–Meier analysis and log-rank test were uti-
lized to curve the overall survical of cervical cancer
patients. The univariate Cox regression was performed
to examine the influence of each clinic-pathological
characteristic on patient survival. And the multivariate
analysis with Cox proportional hazards model for each
variable that were significant in the univariate analysis.
P < 0.05 or less was considered as statistically significant.
Results
Upregulated PAK4 in cervical cancer, correlating with the
cancer’s malignance
There were total of 93 cases of cervical cancer patients
were involved in this study. As shown in table 1, these
patients were aged from 30 to 75 year, with a median
age of 53 years. The detailed tumor clinic-pathological
characteristics of all patients, such as tumor size, HPV
infection, tumor histology and histological grade, FIGO
stage, distant and lymph node metastasis are summa-
rized in table 1. And the PAK4 expression in mRNA
level in the peritumor tissue (more than 2 cm from
tumor tissue) and in tumor tissue in each patient was
examined with RT-qPCR method. Figure 1 demonstrated
that the relative PAK4 mRNA level (with peritumor
mRNA sample as control) was significantly higher in the
tumor specimens, via the two-tailed paired t test (p <
0.0001, R2 = 1802, 95 % confidence interval (0.2545 to
0.6573)). We then re-grouped those samples according
to their PAK4 levels as high PAK4 group (n = 43) and
low PAK4 group (n = 50) (the patient with the relative
PAK4 mRNA level higher than “1” in the tumor sample
than in the peritumor sample was classified into the high
PAK4 group), and the unpaired t test indicated a signifi-
cant difference between the two group (p < 0.0001,
Fig. 1b).
To recognize the association between the PAK4 high
expression and each clinic-pathological characteristic,
we analyzed the statistical difference in age, tumor size,
HPV infection, tumor histology, FIGO stage, lymph
node metastasis, distant metastasis and histological
grade between the high PAK4 and low groups with chi-
square test. And it was indicated in table 1 that there
was no significant difference in age, tumor size, HPV in-
fection, or tumor histology between the two groups of
patients. However, the high PAK4 expression was mark-
edly associated with the FIGO stage, lymph node
metastasis, distant metastasis and histological grade of
these cervical cancer patients. Those patients with
higher FIGO stage (p = 0.00822), with lymph node (p =
Fig. 1 PAK4 is upregulated in cervical cancer specimens and associates
with poor overall survival. a Upregulated PAK4 mRNA level in the
intra-tumor specimens than in the peritumor specimens of cervical
cancer patients, with paired t test; b Increased PAK4 mRNA level in
cervical cancer specimens, with unpaired t test; c Kaplan-Meier survival
analysis for high PAK4 expression level (>1) versus low PAK4 expression
level (≤1) in patients with cervical cancer. Statistical significance was
considered when p < 0.05
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0.00525) or distant (p = 0.02105) metastasis, or with poor
histological grade (p = 0.03464) presented significantly
higher level of PAK4 mRNA in their cervical cancer
specimens.
High PAK4 expression associates with poor prognosis to
cervical cancer patients
To recognize the prognostic value of PAK4 expression
in patients with cervical cancer, we then investigated
the association between PAK4 expression and overall
survival of cervical cancer patients by Kaplan-Meier
analysis and log-rank test. During the follow-up period,
37 of the 93 patients (39.78 %) died within 60 months.
As shown in Fig. 1c, the overall survival time was sig-
nificantly less for patients with higher PAK4 level than
those with lower PAK4 expression (log-rank test: P =
0.0172). And the univariate analysis demonstrated that
the FIGO stage (P = 0.0026), the lymph node metastasis
(P = 0.0048) and the histological grade (P = 0.0375), and
PAK4 expression (P = 0.0014) were significantly associated
with overall survival of cervical cancer patients (Table 2).
However, there was no significant association was found
between each of other clinic-pathological characteristics
and the overall patient survival. In addition, the multivariate
analysis for each significant variable in the univariate ana-
lysis deomonstrated that the FIGO stage (P = 0.0097), the
lymph node metastasis (P = 0.0124), or the PAK4 expres-
sion (P = 0.0073) was independently associated with the
poor prognostic overall survival for patients with cervical
cancer (Table 3).
PAK4 confers cisplatin resistance in cervical cancer cells
in vitro
To further investigate the association of PAK4 with the
poor prognosis of cervical cancer patients, we examined
the influence of PAK4 overexpression on the sensitivity
of Hela and Caski cells to cisplatin. It was indicated in
Fig. 2a that the PAK4 overexpression posed no obvious
influence on the viability of Hela cells, compared to the
control plasmid and the blank control. However, the
cellular viability decreased dramatically post the 5 μM
cisplatin treatment (Column 4 vs Column 1, p < 0.01).
Moreover, the transfection with pcDNA3.1-PAK4 mark-
edly ameliorated the viability reduction by the cisplatin
treatment, compared to the transfection with the
pcDNA3.1-Con plasmid (Column 6 vs Column 5, p <
0.01), whereas there was no significant difference be-
tween the pcDNA3.1-Con-transfected and blank Hela
cells (Column 5 vs Column 4). Then we re-examined
such influence of PAK4 overexpression in Caski cells,
and results demonstrated that the viability of the
pcDNA3.1-PAK4-transfected Caski cells was also sig-
nificantly higher than the pcDNA3.1-Con-transfected
or the blank Caski cells (p < 0.05, Column 6 vs Column
5, Fig. 2b). In addition, we examined the time-
dependence of the cellular viability amelioration by
PAK4 overexpression in the two types of cells. It was
indicated that such amelioration was significant at 24
or 48 h post the transfection in both Hela (p < 0.05 or
p < 0.01, Fig. 2c) and Caski (either p < 0.01, Fig. 2d)
cells. Therefore, PAK4 inhibited the sensitivity of Hela
and Caski cells to cisplatin.









< 65 vs≥ 65 1.261 (0.714-1.906) 0.4362
Tumor size (cm)
< 4 vs ≥4 1.179 (0.706-1.942) 0.4523
HPV
Positive vs Negative 0.875 (0.437-1.691) 0.7831
Tumor histology
Squamous vs Others 0.696 (0.354-1.342) 0.2874
FIGO stage
Ib-IIa vs IIb-IIIa 2.226 (1.416-3.752) 0.0026*
LN metastasis
Positive vs Negative 2.042 (1.318-3.265) 0.0048
Distant metastasis
Positive vs Negative 1.660 (0.980-2.945) 0.0522
Histological grade
Poor vs Well/moderate 1.762 (1.130-2.706) 0.0375
PAK4 expression
High vs Low 2.217 (1.435-3.562) 0.0014
*: with significance









Ib-IIa vs IIb-IIIa 2.53 (1.16-4.68) 0.0097
LN metastasis
Positive vs Negative 1.81 (1.22-2.83) 0.0124
Histological grade
Poor vs Well/moderate 1.45 (0.95-2.40) 0.0683
PAK4 expression
High vs Low 3.21 (1.47-5.35) 0.0073
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To further confirm the effect of PAK4 on cisplatin effi-
cacy, we knockdown the PAK4 expression, and re-
evaluated the cisplatin-mediated viability reduction in
both Hela and Caski cells. Results indicated that PAK4
was significantly downregulated in both mRNA (p < 0.01
for 25 or 50 nM, Fig. 3a) and protein levels (p < 0.001
for 25 or 50 nM, Fig. 3b). And then we also re-examined
the cisplatin-mediated viability reduction in both types
of cells. It was demonstrated in Fig. 3c that the transfec-
tion with 50 nM siRNA-PAK4 significantly aggravated
the cisplatin-mediated viability reduction at either 24 or
48 h post treatment (p < 0.05 or p < 0.01). And Fig. 3d
also indicated that the siRNA-PAK4 transfection mark-
edly deteriorated the cisplatin-mediated viability reduc-
tion at either 24 or 48 h post treatment (p < 0.05
respectively). Therefore, the PAK4 knockdown sensitized
Hela and Caski cells to cisplatin.
PI3K/Akt-dependent pathway is implicated in the PAK4-
confered cisplatin resistance
To explore the mechanism underlying PAK4-induced
cisplatin resistance in cervical cancer cells, we examined
the activation of PI3K/Akt pathway in the cisplatin-
treated Hela and Caski cells, with or without the trans-
fection with siRNA-PAK4 or siRNA-Con. The western
blotting results demonstrated that the PAK4 level was
not markedly regulated by the 5 μM cisplatin treatment
in both cell lines, whereas the phospholylated PAK4 was
promoted by the 5 μM cisplatin treatment (Column 1
and 2, Fig. 4a and b). However, such both PAK4 and p-
PAK4 was significantly downregulated by the transfec-
tion with siRNA-PAK4 (Column 3 and 4, Fig. 4a and b).
Moreover, the phosphorylated AKT was significantly
promoted by the cisplatin treatment in Hela cells. How-
ever, the promotion to the phosphorylated AKT was also
inhibited by the transfection with 50 nM siRNA-PAK4,
compared with the transfection with 50 nM siRNA-Con
(Fig. 4a). And such promotion to the phosphorylated
AKT and the inhibition by siRNA-PAK4 were also con-
firmed in Caski cells (Fig. 4b). To investigate the role of
AKT phosphorylation in the cisplatin resistance in cer-
vical cancer cells, we then measured the viability of
cisplatin-treated Hela and Caski cells, in the presence of
PI3K/Akt inhibitor, LY294002. Figure 4c demonstrated
that there was no significant regulation on the viability
of Hela cells by the treatment with 10 or 20 nM
LY294002. However, the LY294002 treatment markedly
deteriorated the cisplatin-mediated viability reduction of
Hela cells with a concentration of 10 (p < 0.05) or 20 nM
(p < 0.01), dose-dependently (p < 0.05). And such effect
was repeated in Caski cells, either concentration of 15 or
30 nM LY294002 markedly aggravated the cellular
Fig. 2 Overexpressed PAK4 ameliorates the cisplatin-induced viability reduction of cervical cancer cells. a and b: The percent viability of Hela (a)
and CaSki (b) cells which were transfected with control pcDNA3.1 (pcDNA3.1-Con) or pcDNA3.1-PAK4, with or without the treatment with 5 μM
(for Hela cells) or 10 μM (for CaSki cells) cisplatin for 24 h; c and d: Time-dependence of the influence of the transfection with pcDNA3.1-Con or
with pcDNA3.1-PAK4 on the viability of Hela (c) and CaSki (d) cells, in the presence of 5 μM (for Hela cells) or 10 μM (for CaSki cells) cisplatin. All
results were averaged for triple independent experiments. *P < 0.05, **P < 0.01 or ns: no significance
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viability reduction (p < 0.05 or p < 0.01, Fig. 4d), dose-
dependently (p < 0.05). Thus, our results confirmed the
involvement of PI3K/Akt-dependent pathway in the
PAK4-confered cisplatin resistance.
Discussion
PAK4 activation/upregulation has been recognized to be
associated with the malignance in various types of hu-
man cancers, such as cancers in ovarium [27], gaster
[28, 18], hypar [29]. The prognostic value and thera-
peutic potential of PAK4 has been confirmed in ovarian
cancer [27]. PAK4 has been indicated to correlate with
poorer survival in patients with metastatic gastric cancer
[30]. Therefore, these findings suggested that PAK4 is
indicative for the clinical progression and prognosis of
GC. In the present study, we confirmed the upregulation
of PAK4 in the tumor tissues than in the peritumor tis-
sues in 93 cases of cervical cancers; and the PAK4 up-
regulation was markedly associated with the FIGO stage,
lymph node metastasis, distant metastasis and histo-
logical grade of these cervical cancer patients, was
significantly and independently prognostic for the overall
survival time of these patients.
Accumulating evidence has confirmed the mediation
of PAK4 in chemoresistance in various types of cancers.
Recently, PAK4 has been indicated to enhance the sur-
vival and decrease the apoptosis of prostate cancer cells
following chemotherapy [31], and to be a predictive
marker of gemcitabine sensitivity in pancreatic cancer
cell lines [32]. And in gastric cancer, overexpressed
PAK4 has also been suggested to confer the resistance to
capecitabine/cisplatin chemotherapy [30, 24]. In the
present study, PAK4 overexpression posed marked
amelioration of the viability reduction of cervical Hela
and Caski cells post the cisplatin treatment, time-
dependently, whereas the knockout of PAK4 aggravated
the cisplatin-mediated viability reduction in both types
of cells. Therefore, our study confirmed the mediation of
PAK4 in the resistance to cisplatin in Hela and Caski
cells. In addition, the PI3K/Akt-dependent pathway was
implicated in the PAK4-confered cisplatin resistance in
Hela and Caski cells. The phosphorylated AKT was sig-
nificantly promoted by the cisplatin treatment in Hela
Fig. 3 PAK4 knockdown inhibits the cisplatin resistance in cervical cancer cells. a: PAK4 mRNA level in Hela cells which were transfected with the
PAK4-targeted siRNA (siRNA-PAK4) or with the control siRNA (siRNA-Con) with a concentration of 25 or 50 nM; b: Western blot analysis of PAK4 in
protein level in the siRNA-PAK4- or siRNA-Con-transfected Hela cells; C and D: Influence of the transfection with siRNA-PAK4 or with siRNA-Con
on the viability of Hela (c) and CaSki (d) cells, post the treatment with5 μM (for Hela cells) or 10 μM (for CaSki cells) cisplatin for 12, 24 or 48 h.
Each value was averaged for triple independent results. *P < 0.05, **P < 0.01 or ***P < 0.001, ns: no significance
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and Caski cells. However, the promotion to the phos-
phorylated AKT was inhibited by the knockout of PAK4.
On the other side, the PI3K/Akt inhibitor, LY294002
markedly deteriorated the cisplatin-mediated viability re-
duction of Hela and Caski cells. Thus, our results con-
firmed the involvement of PI3K/Akt-dependent pathway
in the PAK4-confered cisplatin resistance.
Conclusion
In summary, this study has confirmed the significant
prognostic role of PAK4 level in cervical cancer patients
and has recognized the regulatory role in cervical cancer
progression. High PAK4 level is correlated with the ad-
vanced stage cervical cancer, and is an independent fac-
tor for predicting the clinical prognosis of patients with
cervical cancer. Moreover, our study has indicated that
PAK4 also confers the chemoresistance of cervical can-
cer cells in a PI3K/Akt-dependent way. Thus, our study
indicates PAK4 as a promising marker for cervical can-
cer treatment.
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